MedtronicTalks

Mike Marinaro, president of the cardiac rhythm management business, explains why CRM employees feel a special connection to Medtronic’s core mission. He also details how the big revenue business is developing new technologies in pacemakers, defibrillators and connectivity to help the business grab market share.

Daniel Volz, the newly named head of Medtronic’s neurovascular group, explains how the company is developing game-changing technologies into devices that will help people who have suffered a stroke or aneurysm. Volz reviews the newest addition to Medtronic’s pipeline as well as its innovative deal with Viz.ai, an artificial intelligence provider.

Geoff Martha, chairman and CEO of Medtronic, updates us on Medtronic’s first-quarter performance. Martha reports the Delta variant has had an impact on revenue, but Medtronic forecasts a return to normal soon. This episode also discusses the Intersect ENT acquisition, the source of future growth and the company’s new metrics on patient safety.

Jacob Paul, senior vice president and president of Medtronic's cranial and spinal technologies group, explains how the company doubled down on the spinal surgery space by committing to significant acquisitions of robotics and artificial technologies that it believes will advance the level of care for spinal surgery patients.

In this episode, Rebecca Seidel, president of cardiac ablation solutions, and Dr. Robert Kowal, vice president, medical affairs and CMO of cardiac rhythm and heart failure, detail how Medtronic is targeting atrial fibrillation, a deadly and far-ranging disease, with Artic Front, a delivery of cryoablation therapies. Medtronic secured a first-time FDA approval, which agrees cryoablation should be offered as an initial treatment for people suffering with atrial fibrillation. Medtronic is moving forward with a unique direct-to-consumer approach and bringing insurance companies in on the conversation. The conversation also hits upon the company’s emerging pulse field ablation therapy.

Two decades ago, Ann Sheldon was drawn to Medtronic by its mission to create devices that people. Today, Sheldon, vice president of security, heads a team that assumes an increasingly essential mission of protecting those devices – and the patient they help – from outsiders that might want to disrupt their performance. In this episode, Sheldon explains what Medtronic is doing to ensure the many benefits of connected devices aren’t impeded by hackers and other outside forces. The company is drawing on many employees and partners from outside the company to create a safe connection between its medical devices and the patients who rely on their optimal performance.

Subscribe to this podcast on Amazon, Apple, Spotify and Google podcast channels.

Dave Anderson, president of the neuromodulation business unit, reports on the advances in neuromodulation technologies including deep brain and spinal cord stimulation. He also updates on the CareGuidePro, a new app developed in partnership with Higgs Boson Health, a physician-led digital health group. Anderson also shed light on the breaking news about Vanta.

In this podcast, Brett Wall, executive vice president and president of Medtronic’s neuroscience portfolio, shares the experiences he’s had working at medtech companies in transformation. Each change brings new lessons that Wall will bring to bear as he leads the company’s neuroscience business. Wall shares the advice given to him from former CEO Omar Ishrak and current CEO Geoff Martha. He also explains how Medtronic will work to instill an innovative spirit in employees without sacrificing the power that comes with being a big company.

Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, says Medtronic’s diabetes unit is reinvigorated by acquisitions, new internally developed products and a partnership with a private equity giant. In this MedtronicTalks podcast episode, Salmon explains why the diabetes community is excited about Medtronic’s pipeline and what the company is doing to meet those higher expectations.

CEO and Chairman Geoff Martha took the helm at Medtronic just as the world was entering the epic pandemic. But the lockdown didn’t slow down Medtronic’s reorganization, a seismic change that Martha and the management team felt was necessary to instill a new “Medtronic Mindset.”

Now one year in, Martha shares his thoughts on the past year. What’s gone well? What could go better? And where is Medtronic looking for growth? He also speaks to the decision to pull] Medtronic’s HeartWare HVAD off the market.